These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12434692)

  • 21. Impact of meningococcal vaccination with combined serogroups A and C polysaccharide vaccine on carriage of Neisseria meningitidis C.
    Fernández S; Arreaza L; Santiago I; Malvar A; Berrón S; Vazquez JA; Hervada X
    J Med Microbiol; 2003 Jan; 52(Pt 1):75-77. PubMed ID: 12488569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of meningococcal C conjugate vaccine in the UK.
    Balmer P; Borrow R; Miller E
    J Med Microbiol; 2002 Sep; 51(9):717-722. PubMed ID: 12358061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
    Thabuis A; Tararbit K; Taha MK; Dejour-Salamanca D; Ronin V; Parent du Chatelet I; Spaccaferri G
    Euro Surveill; 2018 Jul; 23(28):. PubMed ID: 30017022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The decline of the incidence of meningococcal disease in Barcelona between 1988 and 2015: the influence of the vaccine against serogroup C.
    Manzanares-Laya S; Parés-Badell O; Gorrindo P; Simón P; Ros M; de Andrés A; López Segura N; Brió Sanagustín S; Vilella A; Rodrigo Gonzalo de Liria C; Orcau À; Caylà JA
    Med Clin (Barc); 2018 Nov; 151(10):390-396. PubMed ID: 29503027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
    Ramsay ME; Andrews NJ; Trotter CL; Kaczmarski EB; Miller E
    BMJ; 2003 Feb; 326(7385):365-6. PubMed ID: 12586669
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serogroup C
    Findlow H; Campbell H; Lucidarme J; Andrews N; Linley E; Ladhani S; Borrow R
    Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.
    Hellenbrand W; Elias J; Wichmann O; Dehnert M; Frosch M; Vogel U
    J Infect; 2013 Jan; 66(1):48-56. PubMed ID: 23043893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
    Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Northland emergency meningococcal C vaccination programme.
    Mills C; Penney L
    N Z Med J; 2013 Apr; 126(1373):30-9. PubMed ID: 23797074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.
    Campbell H; Andrews N; Borrow R; Trotter C; Miller E
    Clin Vaccine Immunol; 2010 May; 17(5):840-7. PubMed ID: 20219881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.
    Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB
    Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods.
    Monalisa Mendes Dantas Sales N; Azevedo J; Teles Bastos Ribeiro M; Fonseca de Freitas H; Pedreira da Silva Filho H; Machado Cordeiro S; Galvão Reis M; Neves Reis J
    Vaccine; 2020 Sep; 38(40):6267-6273. PubMed ID: 32741673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study.
    Cardoso CW; Ribeiro GS; Reis MG; Flannery B; Reis JN
    PLoS One; 2015; 10(4):e0123734. PubMed ID: 25874777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.